Cannabinoid Type 1 Receptor Antagonists Modulate Transport Activity of Multidrug Resistance-Associated Proteins MRP1, MRP2, MRP3, and MRP4


Department of Pharmacology and Toxicology, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands (H.G.M.W., J.J.M.W.v.d.H., P.H.H.v.d.B., J.B.K., F.G.M.R.); and Abbott Products GmbH, Hannover, Germany (H.D.-H.)

Received December 15, 2010; accepted April 21, 2011

ABSTRACT:

Cannabinoid type 1 (CB1) receptor antagonists have been developed for the treatment of obesity, but a major disadvantage is that they cause unwanted psychiatric effects. Selective targeting of peripheral CB1 receptors might be an option to circumvent these side effects. Multidrug resistance-associated proteins (MRPs) can influence the pharmacokinetics of drugs and thereby affect their disposition in the body. In this study, we investigated the interaction of the prototypic CB1 receptor antagonist rimonabant and a series of 3,4-diarylpyrazoline CB1 receptor antagonists with MRP1, MRP2, MRP3, and MRP4 in vitro. Their effect on ATP-dependent transport of estradiol 17β-glucuronide (E17βG) was measured in inside-out membrane vesicles isolated from transporter-overexpressing human embryonic kidney 293 cells. Rimonabant inhibited MRP1 transport activity more potently than MRP4 (K, of 1.4 and 4 μM, respectively), whereas the 3,4-diarylpyrazolines were stronger inhibitors of MRP4- than MRP1-mediated transport. A number of CB1 receptor antagonists, including rimonabant, stimulated MRP2 and MRP3 transport activity at low substrate concentrations but inhibited E17βG transport at high substrate concentrations. The interaction of 3,4-diarylpyrazolines and rimonabant with MRP1–4 indicates their potential for drug–drug interactions. Preliminary in vivo data suggested that for some 3,4-diarylpyrazolines the relatively lower brain efficacy may be related to their inhibitory potency against MRP4 activity. Furthermore, this study shows that the modulatory effects of the 3,4-diarylpyrazolines were influenced by their chemical properties and that small variations in structure can determine the affinity of these compounds for efflux transporters and thereby affect their pharmacokinetic behavior.

Introduction

The cannabinoid type 1 (CB1) receptor is involved in regulation of feeding behavior, metabolism and energy balance (Di Marzo, 2008). Studies in rodents have shown that antagonism of this receptor leads to reduced food intake and weight reduction (Boyd and Fremming, 2005). Several CB1 receptor antagonists were developed for the treatment of obesity, and clinical studies showed a reduction in appetite, weight loss, and improved metabolic risk factors (Boyd and Fremming, 2005; Bifulco et al., 2009). Rimonabant was the first and only selective CB1 receptor antagonist approved for therapeutic use. However, the drug was withdrawn from the market within 2 years of its introduction, because psychiatric adverse effects, in particular depression, were revealed in additional clinical studies (Jones, 2008; Nissen et al., 2008).

The CB1 receptor is expressed in brain and peripheral tissues such as adipose, skeletal muscle, liver, gut, and pancreas (Di Marzo, 2008). In the brain, activation of the endocannabinoid system appears to be involved in coping with stress and anxiety. Therefore, the psychiatric side effects seen for CB1 receptor antagonists could be due to inhibition of the endocannabinoid system (Bifulco et al., 2009). It is believed that the positive effect of antagonists on metabolic factors could also be mediated via peripheral CB1 receptors (Di Marzo, 2008). Indeed, a recent study with a peripheral CB1 receptor antagonist in obese mice showed that this antagonist could improve the cardiometabolic risk in these mice without inhibition of the central CB1 receptor (Tam et al., 2010). Therefore, peripheral CB1 receptor antagonists might have therapeutic potential for improving metabolic risk in obese patients without causing psychiatric side effects.

Multidrug resistance-associated proteins (MRPs) are efflux transporters that can influence drug disposition by transporting a wide variety of substrates out of the cell (Zhou et al., 2008), preventing drugs from entering specific tissues or organs (e.g., intestine and brain), or increasing elimination of compounds, e.g., via liver and kidney (Yu et al., 2007). MRP1, MRP2, MRP3, and MRP4 belong to the ATP-binding cassette (ABC) transporter subfamily C and have...
overlapping substrate specificities (Kruh and Belinsky, 2003). MRP1 is present in many tissues, with the highest protein expression in lung, adrenal gland, heart, and skeletal muscle, and lower amounts in brain, choroid plexus, spleen, kidney, intestine, testes, placenta, and liver (Flens et al., 1996; Rao et al., 1999; Nies et al., 2004; Leslie et al., 2005). It is expressed basolaterally in most tissues, but it has an apical localization in brain capillary endothelial cells (Nies et al., 2004; Leslie et al., 2005). MRP2 is highly expressed in liver, and lower expression levels can be found in the apical membranes of kidney tubules, gastrointestinal tract, gallbladder, placenta, and bronchi (van Aubel et al., 2000; Nies and Keppler, 2007). MRP3 is expressed in kidney, colon, small intestine, liver, and gallbladder, where it is found mostly in basolateral membranes (Scheffer et al., 2002). MRP4 is widely distributed in tissues and blood cells and has a dual membrane localization, which is basolateral in prostate tubuloacinar cells, hepatocytes, and choroid plexus, and apical in kidney proximal tubule cells and brain capillary endothelium (Nies et al., 2004; Russel et al., 2008). The expression of MRP1–4 at locations that are involved in drug disposition and penetration suggests that they influence drug concentrations in plasma and different organs, and because of their presence in the blood-brain-barrier and choroid plexus, MRP4 and MRP1 might play a role in restricting CB1 receptor antagonists from the brain.

Interaction of a drug with efflux transporters not only can influence its own pharmacokinetics, but it also can change the disposition of other compounds that are substrates for the same transporter. Studies describing the interaction of CB1 receptor antagonists with MRP1–4 may give information not only on the pharmacokinetics of these antagonists but also on possible drug-drug interactions. Here, we investigated the in vitro effect of a series of 3,4-diarylpiperazine CB1 receptor antagonists (Fig. 1) (Lange et al., 2005) and the prototypic CB1 receptor antagonist rimonabant on MRP1–4 transport activity. In addition, for some 3,4-diarylpiperazines, we related their transporter interaction to preliminary in vivo pharmacodynamic effects measured in rats.

Materials and Methods

Materials. [6,7-3H(N)]Estradiol 17-β-α-glucuronide (41.8 Ci/mmol) was purchased from PerkinElmer Life and Analytical Sciences (Groningen, The Netherlands). Bac-to-Bac and Gateway systems, Dulbecco’s modified Eagle’s medium + GlutaMAX-I culture medium, and fetal calf serum were purchased from Invitrogen (Breda, The Netherlands). Triple flasks (500 cm²) were purchased from Sanbio BV Biological Products (Uden, The Netherlands). Estradiol 17-β-α-glucuronide (E₂17βG), adenosine 5’-triphosphate magnesium salt (from bacterial source), and adenosine 5’-monophosphate monohydrate (from yeast) were purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands). Protein concentrations were determined with a Bio-Rad protein assay kit from Bio-Rad Laboratories (Veenendaal, The Netherlands). Monoclonal mouse-anti-human MRP3 antibody M3II-21 was purchased from Abcam (Cambridge, UK). Monoclonal mouse-anti-human MRP1 (QCRL-1) was kindly provided by Dr. S. P. C. Cole (Queen’s University Cancer Research Institute, Kingston, ON, Canada). 3,4-Diarylpiperazine CB1 receptor antagonists (Lange et al., 2005) and rimonabant were kindly provided by Abbott Healthcare Products (Hannover, Germany).

Generation of Baculovirus. Full-length human MRP1, MRP2, and MRP3 were cloned separately into the Gateway pDONR221 vector. The sequence of MRP1 was equal to GenBank accession number NM_004996 except for three silent mutations at base pairs 1684, 1704, and 4002, which are known polymorphisms (Conrad et al., 2001). The sequence of MRP2 was equal to

![Chemical structure of CB1 receptor antagonists](image-url)

**Fig. 1.** Chemical structure of CB1 receptor antagonists. Core structure of 3,4-diarylpiperazine derivatives 4, 11 to 17, and 23 (A) with the chemical structures of R for the N-substituent of these compounds (B) (Lange et al., 2005). C, structure of rimonabant.
NM_000392 except for three silent mutations at base pairs 264, 1167, and 3972, of which C3972T is a known polymorphism (Ito et al., 2001), and the sequence of MRP3 was equal to NM_003786. Consequently, constructs were isolated according to a previously described method with slight modifications (El-Sheikh et al., 2008). In brief, harvested cell pellets were resuspended in 10% fetal calf serum at 37°C under 5% CO2-humidified air. HEK293 cells were cultured in 500 cm2 triple flasks until 40% confluent, after which culture medium was removed and 25 ml of medium and 10 ml of eYFP, MRP1, MRP2, MRP3, or MRP4 baculovirus was added. Cells were incubated for 15 min at 37°C, after which a further 40 ml of medium was added, and 5 mM sodium butyrate was added 24 h after incubation. Three days after incubation, cells were harvested by centrifugation at 5000 g for 5 min.

Isolation of Membrane Vesicles and Protein Analysis. Membranes were isolated according to a previously described method with slight modifications (El-Sheikh et al., 2008). In brief, harvested cell pellets were resuspended in ice-cold homogenization buffer (0.5 mM sodium phosphate and 0.1 mM EDTA) supplemented with protease inhibitors (100 μM phenylmethylsulfonyl fluoride, 5 μg/ml aprotinin, 5 μg/ml leupeptin, 1 μg/ml pepstatin, and 1 μM N-(trans-epoxysuccinyl)-L-leucine 4-guanidinobutylamide (E-64) and shaken trans 1000 g/ml aprotinin, 5 μg/ml leupeptin, 1 μM E-64, and 0.2 mM sodium butyrate) supplemented with unlabeled E217G (7.5 μg/ml) was added in each well to mimic the vesicle environment. The reaction mixture without [3H]E217G was added on ice and only the AMP concentration was measured. The 96-well plate was mixed, and the total reaction mixture from one well was transferred to an Eppendorf tube at room temperature. Sample was spun down at maximal speed (16,000–20,000 g) for 5 min at room temperature and 10 μl of supernatant was reconstituted in 50% acetonitrile-water and 0.1% trifluoroacetic acid (TFA) before LC-MS/MS analysis. Actual concentrations were determined using an Accela ultra-high-performance liquid chromatograph (Thermo Fisher Scientific, Waltham, MA) coupled to a TSQ Vantage (Thermo Fisher Scientific) triple quadrupole mass spectrometer. The CB1 receptor antagonists were separated on a Zorbax Eclipse Plus column (50 × 2.1 mm, 1.8-μm particle size; Agilent Technologies, Santa Clara, CA). The elution gradient was as follows: 0 min, 50% B; 5 min, 90% B; and 6 min, 50% B. Solvent A consisted of 0.1% TFA in ultrapure water, and solvent B consisted of 0.1% TFA in acetonitrile. The column temperature was set at 40°C, and the flow rate was 200 μl/min. The eluent from the high-performance liquid chromatograph was passed directly into the electrospray ion source. Positive electrospray ionization was achieved using a nitrogen sheath gas with ionization voltage at 4 kV. The capillary temperature was set at 350°C. Detection of each analyte was based on isolation of the protonated molecular ion, [M + H]+, and subsequent MS/MS fragmentation and selected reaction monitoring were performed. The conditions per compound are summarized in Table 1. CB1 receptor antagonist 4 or 16 was used as an internal standard, and the response ratio of test compound to internal standard was used to determine the concentration. The actual assay concentration of compound was measured in duplicate in at least three independent experiments.

Vesicular Interaction Assays. To evaluate the inhibitory effects of 3,4-diarylpyrazolines and rimonabant on [3H]E217G uptake in MRP1, 2, 3, and 4 inside-out membrane vesicles, the above-mentioned transport assay was performed in the absence or presence of 10 and 100 μM CB1 receptor antagonists. The concentration-dependent effect of 1 to 100 μM concentrations of compounds 13, 15, and rimonabant was measured at three different E217G concentrations: 0.16, 1, and 5 μM for MRP1; 2, 20, and 200 μM for MRP2; 0.08, 1, and 5 μM for MRP3; and 0.1, 0.3, and 1 μM for MRF4. ATP-dependent transport was calculated.

Determination of Actual Concentrations of 3,4-Diarylpyrazolines and Rimonabant with LC-MS/MS. The actual amount of CB1 receptor antagonists dissolved under vesicular transport assay conditions was measured. eYFP vesicles (7.5 μg/ml) were added in each well to mimic the vesicle environment. The reaction mixture without [3H]E217G was added on ice and only the AMP concentration was measured. The 96-well plate was mixed, and the total reaction mixture from one well was transferred to an Eppendorf tube at room temperature. Sample was spun down at maximal speed (16,000–20,000 g) for 5 min at room temperature and 10 μl of supernatant was reconstituted in 50% acetonitrile-water and 0.1% trifluoroacetic acid (TFA) before LC-MS/MS analysis. Actual concentrations were determined using an Accela ultra-high-performance liquid chromatograph (Thermo Fisher Scientific, Waltham, MA) coupled to a TSQ Vantage (Thermo Fisher Scientific) triple quadrupole mass spectrometer. The CB1 receptor antagonists were separated on a Zorbax Eclipse Plus column (50 × 2.1 mm, 1.8-μm particle size; Agilent Technologies, Santa Clara, CA). The elution gradient was as follows: 0 min, 50% B; 5 min, 90% B; and 6 min, 50% B. Solvent A consisted of 0.1% TFA in ultrapure water, and solvent B consisted of 0.1% TFA in acetonitrile. The column temperature was set at 40°C, and the flow rate was 200 μl/min. The eluent from the high-performance liquid chromatograph was passed directly into the electrospray ion source. Positive electrospray ionization was achieved using a nitrogen sheath gas with ionization voltage at 4 kV. The capillary temperature was set at 350°C. Detection of each analyte was based on isolation of the protonated molecular ion, [M + H]+, and subsequent MS/MS fragmentation and selected reaction monitoring were performed. The conditions per compound are summarized in Table 1. CB1 receptor antagonist 4 or 16 was used as an internal standard, and the response ratio of test compound to internal standard was used to determine the concentration. The actual assay concentration of compound was measured in duplicate in at least three independent experiments.

In Vivo Pharmacodynamic Effect of 3,4-Diarylpyrazolines on CP55,940-Induced Hypotension in Rat. The ED50 of 3,4-diarylpyrazolines for attenuation of 5-(1,1-dimethylheptyl)-2-[5-hydroxy-2-(3-hydroxypropyl)cyclohexyl] phenol (CP55,940)-induced hypotension in male, normotensive, anesthetized Wistar rats was determined according to a method described previously using different intravenous doses (n = 2 per dose) of CB1 receptor antagonists 10 min before CP55,940 (0.1 mg/kg i.v.) administration (Lane et al., 2004). Hypotension was achieved within 1 min after administration of the CB1 receptor agonist CP55,940, and the lowest blood pressure was the measure of the hypotensive effect. ED50 was calculated on the linear part of the percentage dose-response curve and is the dose of antagonist that inhibited the hypotensive effect of CP55,940 by 50%. Experiments were performed in male Wistar rats weighing 300–400 g. CP55,940 was administered as a 1 mg/kg intravenous bolus injection. Rimonabant inhibited the high blood pressure response to CP55,940 in a dose-dependent manner. The dose of rimonabant that inhibited the hypotensive effect of CP55,940 by 50% (ED50) was 1 mg/kg, and the ED50 of rimonabant was 1 mg/kg.

## TABLE 1

<table>
<thead>
<tr>
<th>Compound</th>
<th>Retention Time (min)</th>
<th>Parent (m/z)</th>
<th>Collision Energy (eV)</th>
<th>S Lens</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Product 1</td>
<td>Product 2</td>
</tr>
<tr>
<td>Product 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Product 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>3.2</td>
<td>420.182</td>
<td>255.060 (27)</td>
<td>375.140 (13)</td>
</tr>
<tr>
<td>11</td>
<td>4.2</td>
<td>448.222</td>
<td>255.100 (26)</td>
<td>375.080 (16)</td>
</tr>
<tr>
<td>12</td>
<td>4.2</td>
<td>448.221</td>
<td>255.060 (30)</td>
<td>375.050 (14)</td>
</tr>
<tr>
<td>13</td>
<td>3.8</td>
<td>434.204</td>
<td>255.060 (26)</td>
<td>375.090 (14)</td>
</tr>
<tr>
<td>14</td>
<td>3.5</td>
<td>446.205</td>
<td>255.090 (28)</td>
<td>375.100 (16)</td>
</tr>
<tr>
<td>15</td>
<td>4.8</td>
<td>474.245</td>
<td>255.070 (29)</td>
<td>375.100 (28)</td>
</tr>
<tr>
<td>16</td>
<td>4.8</td>
<td>488.261</td>
<td>255.060 (31)</td>
<td>375.090 (19)</td>
</tr>
<tr>
<td>17</td>
<td>4.0</td>
<td>478.184</td>
<td>255.060 (29)</td>
<td>375.090 (28)</td>
</tr>
<tr>
<td>23</td>
<td>2.6</td>
<td>510.169</td>
<td>255.080 (29)</td>
<td>375.100 (15)</td>
</tr>
<tr>
<td>Rimonabant</td>
<td>3.2</td>
<td>463.163</td>
<td>299.000 (46)</td>
<td>363.020 (29)</td>
</tr>
</tbody>
</table>

Downloaded from asd.materials.org at Radboud Universiteit Nijmegen on July 11, 2012.
were approved by the local ethics committee on animal experimentation at Solvay Pharmaceuticals (Weesp, The Netherlands).

Kinetic Analysis. All data are expressed as means ± S.E.M. Curve-fitting of the resulting concentration-dependent transport curves and determination of IC$_{50}$ values for the CB1 receptor antagonists was performed by nonlinear regression analysis using GraphPad Prism software (version 5.02; GraphPad Software Inc., San Diego, CA). The following equation was fitted to the data: \( y = \frac{y_{\text{bottom}} + (y_{\text{top}} - y_{\text{bottom}})(x - \frac{1}{2})}{(1 + 10^{(x-x_{50})/s})} \) (Hill slope), in which \( x \) is the log inhibitor concentration and \( y \) is expressed as uptake versus control (percentage). A Michaelis-Menten fit was used for MRP1, MRP3, and MRP4 E$_{217}$G curves, and an allosteric sigmoidal fit was used for MRP2. Log (inhibitor or stimulator) versus response with variable slope was used to plot the inhibition and stimulation curves with 13, 15, or rimonabant. Results of the inhibition assay for interaction of MRP1/4 with 13 and rimonabant were analyzed using Dixon’s method combined with linear regression analysis to estimate the inhibitory constant (Ki). Statistical differences were determined using one-way analysis of variance with Dunnett’s multiple comparison test in GraphPad Prism. Differences were considered to be significant at \( p < 0.05 \).

Results

Expression of MRP1, MRP2, MRP3, and MRP4 in Isolated Membrane Vesicles. Immunoblot analysis performed on membrane vesicles from HEK293 cells overexpressing MRP1, MRP2, MRP3, and MRP4 demonstrated that all four transporters were successfully expressed (data not shown). MRP1 seemed to be less glycosylated as indicated by a band at ~160 kDa, but this had no influence on its transport activity (Fig. 2A). The negative control, consisting of membrane vesicles from eYFP-overexpressing HEK293 cells, showed no expression of MRP1–4.

Concentration-Dependent Transport of E$_{217}$G into MRP1-, MRP2-, MRP3-, and MRP4-Overexpressing Membrane Vesicles. Concentration-dependent uptake of E$_{217}$G into membrane vesicles was measured after 5 min for all transporters, and typical curves are shown in Fig. 2, A to D. ATP-dependent E$_{217}$G transport reached maximal activities (V$_{\text{max}}$) of 31 ± 1, 2220 ± 100, and 94 ± 5 pmol·mg$^{-1}$·min$^{-1}$ for MRP1, MRP3, and MRP4, respectively. The affinity of E$_{217}$G (K$_{m}$) for MRP1, MRP3, and MRP4 was 7.5 ± 0.1, 56 ± 6, and 15 ± 3 µM, respectively. Repetition of the experiment for each transporter gave comparable kinetic parameters; only the V$_{\text{max}}$ of MRP3 varied between different batches of membrane vesicles, because of different expression levels of the transporter. Transport activity of MRP2 followed a sigmoidal relationship with increased E$_{217}$G concentration (Fig. 2B). A Hill slope of 1.6 ± 0.03 was calculated for MRP2 activity, which is indicative of positive cooperativity.

Effects of 3,4-Diarylpyrazolines and Rimonabant on MRP1-, MRP2-, MRP3-, and MRP4-Mediated E$_{217}$G Transport. Based on the kinetics of E$_{217}$G uptake by MRP1–4, the following E$_{217}$G concentrations, well below the K$_{m}$, were chosen for interaction studies with 3,4-diarylpyrazolines and rimonabant (Fig. 1): 0.16 µM for MRP1, 20 µM for MRP2, 0.08 µM for MRP3, and 0.12 µM for MRP4. In the case of MRP2, 20 µM substrate was used to measure both stimulation and inhibition.

Figure 3 shows the effect of 10 and 100 µM concentrations of the CB1 receptor antagonists on E$_{217}$G transport by MRP1–4. Because of poor solubility, the actual concentrations of the 3,4-diarylpyrazolines and rimonabant were 3- to 100-fold lower than the predicted concentrations (see legend to Fig. 3). The highest concentration of the series of 3,4-diarylpyrazolines inhibited MRP4 transport activity (Fig. 3D) more potently than MRP1 activity (Fig. 3A). Of the 3,4-diarylpyrazolines, compounds 4 and 12 to 14 significantly inhibited MRP1- and MRP4-mediated E$_{217}$G transport. Compound 13 had the highest inhibitory effect on both transporters, with −34 ± 13 and −72 ± 8% for MRP1 and MRP4, respectively. Transport of E$_{217}$G by MRP1 and MRP4 was not inhibited by compounds 15 to 17 and 23, whereas compound 11 did inhibit MRP4, but not MRP1. Rimonabant inhibited MRP1 more potently than MRP4, viz. −84 ± 4 versus −58 ± 3% (Fig. 3, A and D). In contrast to MRP1 and MRP4, MRP2 transport activity was stimulated by most compounds at both concentrations tested (Fig. 3B). At the lower concentration, compounds 15 to 17 significantly increased uptake of E$_{217}$G into MRP2 vesicles (256–305%). Stimulation of MRP2 was strongest at the high concentration of compounds 4 to 14 (543–734%) and less by compounds 15 to 17 (349–412%) and rimonabant (513%).

![Fig. 2](image_url)
Compound 23 did not significantly increase transport. Figure 3C shows that, although E$_{17}$/G itself inhibited transport, MRP3-mediated E$_{17}$/G transport was significantly stimulated by rimonabant and most 3,4-diarylpyrazolines, of which compounds 11 and 13 had the highest stimulatory effect (155%).

**Mechanism of Modulation of MRP1–4 Transport by Compounds 13, 15, and Rimonabant.** To get a better understanding of the mechanism of interaction, we measured concentration-dependent effects of certain CB1 receptor antagonists on MRP1–4 transport at three different E$_{17}$/G concentrations for each transporter (Fig. 4). 3,4-Diarylpyrazoline derivatives 13 and 15 and rimonabant were selected for further investigation because the magnitude of their effects on the transport activity were different.

Increasing E$_{17}$/G concentrations did not decrease the potency of 3,4-diarylpyrazolines 13 and 15 and rimonabant for inhibiting MRP1 and MRP4 (Fig. 4, A–C and J–L); the percentage of inhibition and the IC$_{50}$ values of 13 and rimonabant for MRP4 and MRP1 were similar at different E$_{17}$/G concentrations. Dixon plots for 13- and rimonabant-mediated inhibition of MRP4 and MRP1 show that the lines intersected virtually at the x-axis for both compounds, which is indicative of noncompetitive inhibition (Fig. 5, A–C). The intersections corresponded to a $K_i$ of ~1.4 µM rimonabant for MRP1, ~4 µM rimonabant for MRP4, ~12 µM rimonabant for MRP2, and ~33 µM rimonabant for MRP3.

**Fig. 3.** Effect of CB1 receptor antagonists on ATP-dependent transport of E$_{17}$/G into MRP1- (A), MRP2- (B), MRP3- (C), or MRP4-overexpressing (D) membrane vesicles. Transport was measured during 5 min at concentrations of 0.16, 20, 0.08, and 0.12 µM E$_{17}$/G, for MRP1, MRP2, MRP3, and MRP4, respectively, in the absence or presence of CB1 receptor antagonists. Because of their poor solubility, concentrations in the low range varied between 0.4 and 2.2 µM (un) and between 4 and 33 µM (m) for the 10-fold higher range. Actual concentrations of CB1 receptor antagonists corresponding to the gray bars were 2.2 µM for compound 4, 0.7 to 1.3 µM for compounds 11 to 17 and 23, and 0.4 µM for rimonabant. Actual concentrations corresponding to the black bars were 33 µM for CB1 receptor antagonist 4, 7 µM for compounds 11 and 12, 12 µM for compounds 13 and 14, 1 to 3 µM for compounds 15 to 17 and 23, and 4 µM for rimonabant. ATP-dependent uptake in the absence of CB1 receptor antagonists was set at 100% (un) and was also measured in the presence of 100 µM E$_{17}$/G (m). Means ± S.E.M. of three independent experiments are shown. Statistically significant differences from vehicle control: *, p < 0.05; **, p < 0.01; ***, p < 0.001.
μM rimonabant for MRP4, and ~7 μM 13 for MRP4. 3,4-Diarylpyrazoline 15 did not inhibit MRP1 transport activity at any of the concentrations tested and only moderately inhibited MRP4 (Fig. 4, A–C and J–L).

MRP2-mediated transport was stimulated by compounds 13, 15, and rimonabant at the lowest \( E_{217G} \) concentration of 2 μM (Fig. 4D). Stimulation was decreased at 20 μM \( E_{217G} \), and transport was inhibited at 200 μM \( E_{217G} \) (Fig. 4, D–F). Rimonabant and compound 15 appeared to have the same stimulatory and inhibitory potency on MRP2-mediated transport.

MRP3-mediated \( E_{217G} \) transport was stimulated at a low substrate concentration, which gradually disappeared at higher substrate concentrations (Fig. 4, G–I). At a concentration of 15 μM \( E_{217G} \), high concentrations of compounds 13 and 15 and rimonabant inhibited \( E_{217G} \) transport via MRP3 (data not shown).

In Vivo Pharmacodynamic Effect of 3,4-Diarylpyrazolines on CP55,940-Induced Hypotension in Rat. To get an impression of the relative brain penetration of the 3,4-diarylpyrazolines, the CB1 receptor-mediated blood pressure effect of compounds 4, 11, 14, and 15 was compared with their in vitro CB1 receptor binding affinity. For this purpose, in rats, we measured the initial rapid effect of CB1 receptor antagonists on CP55,940-induced hypotension, which is considered to originate primarily from a central sympathetic response (Vollmer et al., 1974). Table 2 describes the effective intravenous dose (ED\(_{50}\)) that was needed for 50% inhibition of the hypotensive effect of CP55,940 and the binding affinity (expressed as \( K_i \)) of these compounds for the CB1 receptor, as determined previously (Lange et al., 2005). The in vivo data show that CB1 receptor antagonist 15 had the lowest ED\(_{50}\) value. If the ED\(_{50}\) of 15 relative to its binding affinity is extrapolated to compounds 4, 11, and 14 on basis of their \( K_i \) values for...
Unlike MRP1, MRP3, and MRP4, MRP2 transported E217 in the literature (Loe et al., 1996; Zeng et al., 2000; Chen et al., 2001).

The reciprocal of transport velocity (1/V) of different substrate concentrations is plotted against the inhibitor concentration. Dixon plots of inhibition of MRP1 (A) and MRP4 (B) by rimonabant and of MRP4 by compound 13 (C) at three different E217G concentrations are shown. 0.16 μM (□), 1 μM (●), and 5 μM (▲) E217G MRP1 for MRP1 and 0.1 μM (■), 0.3 μM (●), and 1 μM (▲) E217G for MRP4. Linear regression analysis was used for plotting lines and determination of $K_i$. Data represent the mean 1/V of duplicate measurements in a representative experiment.

FIG. 5. Dixon plots of inhibition of MRP1- and MRP4-mediated ATP-dependent E217G transport by rimonabant and 3,4-diarylpyrazoline 13. The reciprocal of transport velocity (1/V) of different substrate concentrations is plotted against the inhibitor concentration. Dixon plots of inhibition of MRP1 (A) and MRP4 (B) by rimonabant and of MRP4 by compound 13 (C) at three different E217G concentrations are shown. 0.16 μM (●), 1 μM (●), and 5 μM (▲) E217G MRP1 for MRP1 and 0.1 μM (■), 0.3 μM (●), and 1 μM (▲) E217G for MRP4. Linear regression analysis was used for plotting lines and determination of $K_i$. Data represent the mean 1/V of duplicate measurements in a representative experiment.

Table 2
Pharmacodynamic characteristics of the CB1 receptor antagonists

<table>
<thead>
<tr>
<th>Compound</th>
<th>CB1a ($K_i$)</th>
<th>ED50</th>
<th>nM</th>
<th>mg/kg i.v.</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>223 ± 103</td>
<td>&gt;0.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>30 ± 14</td>
<td>0.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>231 ± 66</td>
<td>0.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>155 ± 69</td>
<td>0.1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

$^a$ CB1a, displacement of specific CP55,940 binding in CHO cells stably transfected with human CB1 receptor, expressed as $K_i$ ± S.E.M. Data were adapted from Lange et al. (2005).

$^b$ Dose of CB1 receptor antagonist that attenuates CP55,940-induced hypotension in rats ($n = 2$/dose) by 50%.

Discussion

This study shows that CB1 receptor antagonists interacted with the efflux transporters MRP1, MRP2, MRP3, and MRP4. E217G was used as a model substrate to investigate the effect of CB1 receptor antagonists on transport activity of these transporters. The kinetic parameters for E217G found in this study were comparable to those in the literature (Loe et al., 1996; Zeng et al., 2000; Chen et al., 2001). Unlike MRP1, MRP3, and MRP4, MRP2 transported E217G in a positive cooperative manner, which was previously demonstrated by others (Bodó et al., 2003a; Zelcer et al., 2003).

Actual tested concentrations of the very lipophilic CB1 receptor antagonists in the experimental assays were determined by LC-MS/MS and were 3- to 100-fold lower than expected. This result may be due to incomplete dissolution or nonspecific binding. In our study, compounds 15 to 17 stimulated MRP2 better than compounds 4 to 14 at low concentrations. In contrast, the opposite was found at higher concentrations, at which the actual concentrations of compounds 15 to 17 were lower (1–3 μM) than those of 4 to 14 (7–33 μM) (Fig. 3). This result indicates that compounds 15 to 17, which contain N-substituents that make them more lipophilic, have a higher potency in affecting MRP2 but have a limited effect because of their low solubility. The same was found for MRP3, and the lack of effect of compounds 15 to 23 on MRP1 and MRP4 might also be explained by their low actual concentrations.

Although we used E217G as a substrate for all transporters, the effect of the CB1 receptor antagonists on transport of this substrate via MRP1–4 was different. MRP1- and MRP4-mediated transport was inhibited by several CB1 receptor antagonists. The inhibitory affinity of rimonabant was somewhat higher for MRP1-mediated E217G transport than for MRP4-mediated transport, with a $K_i$ of ~1.4 μM versus ~4 μM. The maximal plasma concentration found in male human subjects treated with a therapeutic dose of rimonabant is 0.4 μM (Turpault et al., 2006). Rimonabant and 3,4-diarylpyrazoline 13 appeared to inhibit MRP1 and MRP4 in a noncompetitive manner (Fig. 5, A–C). In addition, MRP1 and MRP4 were stimulated at low substrate and rimonabant concentrations, indicating that rimonabant probably does not compete for the E217G binding site of either transporter (Fig. 4, A and J). Whether rimonabant and the 3,4-diarylpyrazolines are only inhibitors or are also substrates of MRP1 or MRP4 cannot be concluded from this study.

In contrast to MRP1 and MRP4, MRP2-mediated transport was stimulated by all CB1 receptor antagonists, except for compound 23. The results presented in this study suggest that 3,4-diarylpyrazolines and rimonabant stimulate MRP2 allosterically at low E217G concentrations and compete for the E217G binding site at high concentrations. This type of interaction is supported by other studies (Bakos et al., 2000; Evers et al., 2000; Zelcer et al., 2003). The study of Zelcer et al. (2003) showed that several aromatic compounds, most of them containing sulfone or tosyl groups, stimulate MRP2-mediated transport of E217G into membrane vesicles. Compounds that normalized the stimulated transport rates at increasing concentrations, such as sulfipyrazone and indomethacin, also appeared to be substrates for MRP2 (Evers et al., 2000; Zelcer et al., 2003). 3,4-Diarylpyrazolines chemically resemble sulfipyrazone, which, together with the fact that compounds 13 and 15 and rimonabant might compete with E217G at higher substrate concentrations, could indicate that they are substrates for MRP2.

The CB1 receptor antagonists had comparable effects on MRP3 transport activity, but their effects were less pronounced than those for MRP2 (Fig. 4, G–I). Other studies reported that MRP3-mediated E217G transport activity can be inhibited as well as stimulated by different compounds, e.g., 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate, indomethacin, and benz bromarone (Akit a et al., 2002; Bodó et al., 2003a,b). This result indicates that the 3,4-diarylpyrazolines and rimonabant would interact with the CB1 receptor, $ED_{50}$ values of 0.14, 0.02, and 0.15 mg/kg, respectively, would have been expected. However, the actual $ED_{50}$ values of compounds 4, 11, and 14 (Table 2) were >2, ~10, and ~4.7 times higher than expected, indicating a lower brain permeability compared with that for compound 15.
with a modulating site and the substrate site of MRP3, causing 
stimulation of E2β3G transport at low substrate concentrations and 
inhibition at higher substrate concentrations because of competition 
for the substrate site.

Our results show that rimonabant and 3,4-diarylpyrazolines can 
modulate MRP1–4 transport activity, which implies the possibility of 
drug-drug interactions. Because of the brief clinical use of rimon-
abant, few data are available on its in vivo interaction potential with 
drug transporters. Rimonabant was found to moderately affect the 
pharmacokinetics of the P-glycoprotein (ABC1) substrate cyclo-
sporine, but not of tacrolimus and digoxin (Kanamururu et al., 2005; 
Amundsen et al., 2009).

The pharmacokinetic data available for rimonabant do not suggest 
an important role for the MRPs in determining its disposition. Rimo-
abant is shown to accumulate in fat tissue, spleen, thyroid, thymus, 
liver, plasma, and brain and is reported to cross the placental barrier 
(Barna et al., 2009) (European Medicines Agency-European Public 
Assessment Reports scientific discussion about rimonabant, http://
though rimonabant showed a strong interaction with MRP1, its accu-
sloration in the brain and passage across the placental barrier indicates 
that it is either a poor substrate of this transporter, or MRP1 is not 

MRP1 and MRP4 are expressed at the blood-brain-barrier and the 
choroid plexus, where these transporters could be involved in limiting 
the brain penetration of the 3,4-diarylpyrazolone CB1 receptor antag-
onists. Because there are only minor differences in the structures of 
the 3,4-diarylpyrazolines, the rate and extent of passive diffusion of 
these compounds into the brain and other tissues is expected to be 
similar, which should reflect in a similar relationship between ED50 
and CB1 receptor binding affinity (Ki). However, there was a differ-
ence in ED50 values for compounds 4, 11, 14, and 15, which could not 
only be solely attributed to differences in CB1 receptor binding affinities.

The ED50 values of compounds 4, 11, and 14 relative to their Ki 
values were higher compared with the ED50/Ki ratio of compound 15 
(Table 2). This finding suggests that an active mechanism is lowering 
the concentration of compounds 4, 11, and 14 at the site of action, 
resulting in increased ED50 values. The rapid hyotensive action of 
CB1 receptor agonists was shown to be primarily dependent on 
centrally mediated sympathetic tone (Vollmer et al., 1974), which 
could indicate that compounds 4, 11, and 14 but not 15 have higher 
ED50 values because they are less brain-permeable. Our in vitro data 
suggest that MRP4 might be involved. To draw definite conclusions 
about the involvement of Mrp1–4 in influencing tissue concentra-
tions of 3,4-diarylpyrazolines, in vivo studies should be performed 
using specific transport inhibitors and/or Mrp knockout mice.

In addition, it will be important to measure direct transport of CB1 
receptor antagonists by MRP1–4 in vitro. Isolated membrane vesicles 
are probably not useful for this purpose because of the high nonspecific 
binding to lipid membranes and high passive diffusion of the lipophilic 
CB1 receptor antagonists (H. G. M. Wittgen, J. B. Koenderink, and 
F. G. M. Russel, unpublished results). Cell-based accumulation or vec-

torial transport studies may be more suitable. Furthermore, the role of 
the blood-brain barrier and intestinal ABC transporters P-gp and breast 
cancer resistance protein (ABC2G) as possible CB1 receptor antagonist 
eflux pumps should be investigated. The role of influx transporters 
should also be considered in the tissue distribution of the CB1 receptor 
antagonists, but it is to be expected that uptake of these lipophilic 
compounds will be governed largely by passive diffusion.

In conclusion, we have shown that 3,4-diarylpyrazolines and ri-
monabant inhibited MRP1- and MRP4-mediated E2β3G transport 
and stimulated MRP2- and MRP3-mediated transport at low E2β3G 
concentrations. Stimulation of MRP2 and MRP3 shifted to inhibition 
at increasing substrate concentrations. The effect of these compounds 
transport activity of MRP1–4 shows the potential for possible 
drug-drug interactions. Preliminary in vivo data suggested that MRP4 
could be involved in the lower brain permeability of some of the 
3,4-diarylpyrazolines. The actual role of MRPs in tissue distribution 
of 3,4-diarylpyrazolines and rimonabant remains to be investigated. In 
addition, this study shows that the modulatory effects of the 3,4-
diarylpyrazolines were influenced by the properties of their N-sub-
stituent, which indicates that small variations in their chemical struc-
ture can determine the affinity for the efflux transporters and thereby 
possibly affect their pharmacokinetic behavior.

Acknowledgments
We thank Tiny J. P. Adolfs from Abbott Healthcare Products B.V. (formerly 
Solvay Pharmaceuticals) for providing the in vivo pharmacology data. We also 
thank Dr. Kevin Weigl (Abbott Products GmbH) for critical reading of the 
manuscript.

Authorship Contributions
Participated in research design: Wittgen, Dinter-Heidorn, Koenderink, and 
Russel.
Conducted experiments: Wittgen and van den Heuvel.
Contributed new reagents or analytic tools: van den Broek and Dinter- 
Heidorn.
Performed data analysis: Wittgen and van den Heuvel.
Wrote or contributed to the writing of the manuscript: Wittgen, Koenderink, 
and Russel.

References
of human MRP3 expressed in S9 cells: comparative studies with rat MRP3. Pharm Res 
19:34–41.
Rimonabant affects cyclosporine A, but not tacrolimus pharmacokinetics in renal transplant 
interaction of the multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol 76:760–
768.
Barna I, Till E, and Haller J (2009) Blood, adipose tissue and brain levels of the cannabinoid 
ligands WIN-55,212 and SR-141716A after their intraperitoneal injection in mice: compound-
specific and area-specific distribution within the brain. Eur Neuropsychopharmacol 19:533–
541.
Bifulco M, Santoro A, Laezza C, and Malfitano AM (2009) Cannabinoid receptor CB1 antag-
onists: state of the art and challenges. Vitam Horm 81:159–189.
human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J Biol Chem 278:23529–
23537.
Chen ZS, Lee K, and Krah GD (2001) Transport of cyclic nucleotides and estradiol 17β-
glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thiogua-
human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V 
Di Marzo V (2008) CB1 receptor antagonism: biological basis for metabolic effects. Drug Discov 
nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2 and 
role of arginine 375 in transmembrane helix 6 of multidrug resistance protein 4 (MRP4/ 
Vinblastine and sulfisoxazole export by the multidrug resistance protein MRP2 is associated 
transporter genes, MDR1, MRP1 and MRP2/CMOAT, in healthy Japanese subjects. Pharma-


Address correspondence to: Dr. F. G. M. Russel, Department of Pharmacology and Toxicology (149), Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. E-mail: f.russel@pharmtox.umcn.nl